JP2023548055A - 癌をアルキン置換キナゾリン誘導体で治療する方法 - Google Patents

癌をアルキン置換キナゾリン誘導体で治療する方法 Download PDF

Info

Publication number
JP2023548055A
JP2023548055A JP2023524708A JP2023524708A JP2023548055A JP 2023548055 A JP2023548055 A JP 2023548055A JP 2023524708 A JP2023524708 A JP 2023524708A JP 2023524708 A JP2023524708 A JP 2023524708A JP 2023548055 A JP2023548055 A JP 2023548055A
Authority
JP
Japan
Prior art keywords
compound
egfr
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548055A5 (https=
Inventor
バック エリザベス
オコナー マシュー
ロマシュコ ダーリーン
リン タイ－アン
フロール アレクサンダー
アリスタ ルカ
ローナ イウォナ
ルーカス マシュー
ロバーツ クリス
オッタビアニ ギオルギオ
スミス シェリ
ウォーターズ ニゲル
Original Assignee
ブラック ダイアモンド セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブラック ダイアモンド セラピューティクス，インコーポレイティド filed Critical ブラック ダイアモンド セラピューティクス，インコーポレイティド
Publication of JP2023548055A publication Critical patent/JP2023548055A/ja
Publication of JP2023548055A5 publication Critical patent/JP2023548055A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023524708A 2020-11-02 2021-11-02 癌をアルキン置換キナゾリン誘導体で治療する方法 Pending JP2023548055A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063108645P 2020-11-02 2020-11-02
US63/108,645 2020-11-02
US202163166045P 2021-03-25 2021-03-25
US63/166,045 2021-03-25
US202163190067P 2021-05-18 2021-05-18
US63/190,067 2021-05-18
US202163218717P 2021-07-06 2021-07-06
US63/218,717 2021-07-06
US202163237782P 2021-08-27 2021-08-27
US63/237,782 2021-08-27
US202163244540P 2021-09-15 2021-09-15
US63/244,540 2021-09-15
PCT/US2021/057724 WO2022094464A1 (en) 2020-11-02 2021-11-02 Method of treating cancers with alkyne substituted quinazoline derivatives

Publications (2)

Publication Number Publication Date
JP2023548055A true JP2023548055A (ja) 2023-11-15
JP2023548055A5 JP2023548055A5 (https=) 2024-11-13

Family

ID=78819639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524708A Pending JP2023548055A (ja) 2020-11-02 2021-11-02 癌をアルキン置換キナゾリン誘導体で治療する方法

Country Status (10)

Country Link
US (1) US20240075042A1 (https=)
EP (1) EP4236954A1 (https=)
JP (1) JP2023548055A (https=)
KR (1) KR20230093429A (https=)
AU (1) AU2021368798A1 (https=)
CA (1) CA3195473A1 (https=)
IL (1) IL302329A (https=)
MX (1) MX2023004998A (https=)
TW (1) TWI910256B (https=)
WO (1) WO2022094464A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598A1 (en) 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CA3231697A1 (en) * 2021-09-21 2023-03-30 Black Diamond Therapeutics, Inc. Polymorphs as erbb inhibitors
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
WO2025128831A1 (en) * 2023-12-13 2025-06-19 Black Diamond Therapeutics, Inc. Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518544A (ja) * 2011-03-04 2014-07-31 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
JP2022502495A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518544A (ja) * 2011-03-04 2014-07-31 ニューゲン セラピューティクス， インコーポレイテッド アルキン置換キナゾリン化合物および使用方法
WO2021030711A1 (en) * 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Also Published As

Publication number Publication date
TWI910256B (zh) 2026-01-01
IL302329A (en) 2023-06-01
AU2021368798A9 (en) 2023-07-06
KR20230093429A (ko) 2023-06-27
MX2023004998A (es) 2023-05-12
EP4236954A1 (en) 2023-09-06
WO2022094464A1 (en) 2022-05-05
US20240075042A1 (en) 2024-03-07
CA3195473A1 (en) 2022-05-05
AU2021368798A1 (en) 2023-05-18
TW202235083A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
JP2023548055A (ja) 癌をアルキン置換キナゾリン誘導体で治療する方法
WO2023140329A1 (ja) がんの治療または予防用医薬
JP5778735B2 (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
JP6038650B2 (ja) Ｄｌｌ４アンタゴニスト及び化学療法剤を用いたがんの治療方法
JP2024109885A (ja) 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
JP2022527151A (ja) クローディン６抗体及び薬物複合体
JP2025122018A (ja) Ｂｃｌ９ペプチドおよびそのバリアント
JP2022502496A (ja) チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
EP3083695A1 (en) Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy
JP2026048890A (ja) 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ
JP2012211158A (ja) 細胞外アンタゴニストおよび細胞内アンタゴニストによる受容体チロシンキナーゼの抑制方法
US20130142796A1 (en) Treatment for angiogenic disorders
WO2025038731A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
CN116710096A (zh) 用炔取代的喹唑啉衍生物治疗癌症的方法
JP2021501160A (ja) 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
JP2023542296A (ja) Ｆｇｆｒ阻害剤の併用療法
KR20260053328A (ko) 알킨 치환된 퀴나졸린 유도체를 이용한 암 치료 방법
EP4534085A1 (en) Compounds for use in methods of treating cancer
WO2025166725A1 (en) Antibody-drug conjugate
WO2025054996A1 (en) Antibody-drug conjugate
JP7848119B2 (ja) 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ
TWI920018B (zh) 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途
WO2026064728A1 (en) Method of treating cancers with alkyne substituted quinazoline derivatives
HK40085220A (en) Antibody drug conjugate formulation and use thereof
Mettu et al. How I Treat Metastatic Colorectal Cancer With Emerging Therapeutic Strategies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421